The expression of DNASE1L3 is associated with the prognosis of HCC with DNA damage treatment or anti-angiogenesis such as TACE or solafenib (Figure 1 and Supplementary Figure 1). Here, DNASE1L3 is linked to hepatocellular carcinoma.